Indian Pharmaceutical Market - An Overview

50000 Total IPM & Incremental Value (in Rs. Cr.) YoY
45000 43823
40000 36630
Val. (Rs. Cr.)

35000 32856
30000 28841
25000
20000
15000
10000 7193
5000 3534 4015 3774
0
JUN '07 MAT JUN '08 MAT JUN '09 MAT JUN '10 MAT
Incr. Value ( Rs. Cr.) Value ( Rs. Cr.)

IPM is growing at 19.6%, which is the

highest growth since 4 years, with a
CAGR of 15.2%
1
 Growth Drivers of IPM

 Macroeconomic Environment – Strong GDP growth,

Rapid urbanization, Govt. initiatives, changing
demographics & development of biologics.

 Healthy Environment – Increase private & govt.

spending & increase access to lower class towns.

 Robust Market Trend – We observe that IPM is on a

high growth trend for the past year after a relatively
low profile in 2008-09.
2
 Chart 4- Growth Drivers Of the IPM
Figures in () indicate value growth of IPM in %
25
(20)

20
(14)
7
% growth

15 (11)

1
10 8
7
1 12
5
1
5
3
0
Jun '08 MAT Jun '09 MAT Jun '10 MAT
NI Growth% Price-led Growth% Vol. Growth%

3
 Table 1: Performance of NI over the last 4 years
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT

Value of IPM (`Cr.) 28,841 32,856 36,630 43,823

No. Of NI 4,810 4,285 4,365 4,562

Value of NI (Cr.) 2,166 2,183 2,438 2,719

Contribution to IPM (%) 7.5 6.6 6.7 6.2

4
 Value of IPM (Cr.) No. Of NI
43,823 4,810
36,630
32,856
28,841 4,562

4,365
4,285

Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT

Contribution to IPM (%)

Value of NI (Cr.)
Contribution to IPM (%)
2,719
2,438 7.5
2,166 2,183 6.6 6.7
6.2

Jun '07 Jun '08 Jun '09 Jun '10

MAT MAT MAT MAT Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT

Performance of NI over the last 4 5

years
 Table 2: No of NIs above Rs. 10 Cr.

Jun ‘07 MAT Jun ’08 MAT Jun ’09 MAT Jun ’10 MAT

No. of NIs above Rs. 10 Cr. 10 10 15 20

Value of NIs above Rs. 10 Cr. 135 165 300 438

Contribution of NIs above Rs. 10

6.2% 7.5% 12.3% 16.1%
Cr. to total NI value

Value of largest NIs (Rs. Cr.) 23.3 30.9 52.1 81.4

6
 Top 10 New Introductions as per ‘JUN 10 MAT
S. No. Brand Company Sub-group Prod. Launch Val
YYYY-MM ( Rs. Cr.)
IPM 2718.9
1 AEROCORT* CIPLA R03CK SALBUTAMOL + BECLOMETHASONE 2008 - 08 81.4
2 A TO Z NS* ALKEM A11A4 OTH. MULTIVIT.-MIN. SOLID 2008 - 11 28.5
3 JANUMET MSD A10BT ANTIDAIBETICS COMBINATIONS 2008 - 12 27.8
(METFORMIN +SITAGLIPTIN)
4 MTP KIT CIPLA G03K1 MIFEPRISTON 2009 - 02 26.3
5 GALVUS NOVARTIS A10BE OTHER ANTIDIABETICS-PLAIN 2008 - 08 26.3
(VILDAGLIPTIN)
6 MTPROST KIT CIPLA G03K1 MIFEPRISTON 2009 - 02 26.2
7 POLYBION SF* MERCK A11E8 OTH. [Link] 2009 - 06 25.1
LIQIUDS
8 POLYBION-LC* MERCK A11E8 OTH. [Link] 2009 - 03 20.9
LIQIUDS
9 NORFLOX-TZ* CIPLA P01A6 TINI+ OTH. COMBINATION SOLID 2008 - 12 20.5
10 JALRA USV A10BE OTHER ANTIDIABETICS-PLAIN 2009 - 01 19.9
(VILDAGLIPTIN)

* REFORMULATIONS 7
 Insights
 Among products that were launched New packs/ Reformulations
showed the highest gain.
 New Introduction by Cipla constituted to 51% amongst top ten
Brands. Demonstrating their success in brand building.
 Antidiabetics form the major therapy amongst new Introduction,
indicating a strong potential in the segment.
 Among the top 10 companies in IPM, only Cipla & Alkem are
reflected in top 10 new introductions.
 6/10 NI are combinations, thus indicating continued focus on
combination drugs in India
 Mifepriston brands together account for Rs. 50 Cr. within a year of
launch, thus indicating the huge potential of the contraceptive
market

8
 Top 10 brands (Jun’ 10 MAT)
Value Growth %
Rank (G/L Brand Company Value Incr. Value
over last year     (Rs. Cr.) (Rs. Cr.)
    Jun' 09 MAT Jun'10 MAT

  IPM   43,823 7,193 11 20

1(1) Corex Pfizer 204 32 17 19

2(-1) Phensedyl Piramal Healthcare 203 24 17 19

3(0) Voveran Novartis 159 24 6 18

4(3) Augmentin GSK 158 38 10 31

5(0) Human Mixtard 30/70 Abbott 157 32 3 26

6(7) Revital Ranbaxy 152 47 29 45

7(4) Becosules Pfizer 140 30 15 27

8(1) Dexorange Franco Indian 140 26 16 22

9(-1) Zifi FDC 138 23 8 20

10(2) Monocef Aristo Pharma 136 26 24 24

9
 INSIGHTS
 Cipla despite being the no. 1 company does not have a single brand in Top 10 products.

 Except for Human Mixtard 30/70 (Abbott)- used for Chronic Therapy, Acute therapy still
has a strong foothold in the Top 10 brands.

Corex (204Cr.) & Phensedyl (203Cr.), both cough syrups occupying No.1
& 2 position respectively, are going neck to neck.

 Zifi (FDC) & Monocef (Aristo), No.9 & 10 brands respectively, belong to the same class
- Cephalosporins.

 Zifi with a value growth of 20% in Jun’ 10 MAT compared to 8% in Jun’09 MAT shows
positive signs for Sub-class- Cefixime.

 Augmentin (GSK) shows the 2nd highest incremental value of Rs.38Cr. even after 30
years of its launch.

10
 Contribution of Indian Companies & MNC’s to IPM

100% 28,841 32,856 36,630 43,823

90% 20 19 19 19
80%
70%
% contribution

60%
50% MNC's
40% 80 81 81 81 Indian Companies

30%
20%
10%
0%
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT

11
 INSIGHTS

 With MNC’s looking out for Inorganic growth in IPM, the figures are bound to
improve for MNC’s in near future.(e.g. Abbott-Piramal)

12
Growth drivers of
Indian Cos.
Vs
MNCs

13
 INDIAN COS. MNC
20 25
18
16 20
8 5
14 1
15
12

% Growth
0
% Growth

9
10
10 5
8 9 15
2 3
6 1 11
5 1
4 5 4
5 1
2 2 0
Jun'08 Jun'09 Jun'10
0 MAT MAT MAT
Jun'08 Jun'09 Jun'10
MAT MAT MAT
Vol Growth %
Vol growth % Price led growth % Price led Growth %
NI Growth % NI Growth %
14
Top 10 companies in the IPM

15
 Top 10 companies in the IPM

Rank Companies Val MS G/L in MS Incr. value Val growth

(Jan’10 MAT) (Rs. Cr.) (%) over last year (Rs. Cr.) (%)
1. Cipla 2,311 5.3 -0.04 365 19
2. Ranbaxy 2,104 4.8 -0.2 273 15
3. GSK 1,872 4.3 -0.03 295 19
4. Piramal 1,835 4.2 -0.03 288 19
Healthcare
5. Zydus 1,641 3.7 0.1 319 24
Cadila
6. Sun 1,625 3.7 0.2 345 27
Pharma
7. Alkem 1,413 3.2 0.1 258 22
8. Pfizer 1,370 3.1 0.1 245 22
9. Mankind 1,298 3.0 0.3 340 35
10. Abbott 1,243 2.8 0.1 239 24

16
 Growth Drivers of Top companies
40 (35)
35
(27)
30 (22) 13
(24)
(19) (22) (24)
25 (19) (19)
(15)
% Growth

7 9 1
6 2 3
20
1 4 3
15 5
12 13 24
10 17 18 18 17
20
16
1 11 1
5
6 5
0 -1 -1
-5
-5
Cipla Ranbaxy GSK Piramal Zydus Sun Alkem Pfizer Mankind Abbott
Healthcare Cadila Pharma

NI Growth % Price Led Growth % Volume Growth %

Figures in () indicate value growth of IPM in %

17
 Company Turnover & Growth Grid
Value Growth (%) Turnover > Rs. 250 Cr. Turnover Rs. 100 - Rs. 250 cr. Turnover Rs.60–
Rs.100Cr.
High Elder Pharma, Mankind, Hegde & Hegde, Geno, Meyer Troikaa Pharma, Tablets
>20% Macleods, Intas, Sun Pharma, Organics, Win Medicare, Eli India, Baidyanath, East
MSD, Unichem, Zydus Cadila, Lilly, Allergan, Wanbury, India, UCB Pharma, TTK
Abbott, Sanofi Aventis, Microlabs, Systopic, Orchid Chem & Healthcare Ltd.
USV, Alkem, DRL, Franco Indian, Pharma, Centaur, Blue Cross,
Indoco, Pfizer, Merck Ltd, Hetero Healthcare
Alembic, Glenmark, Novartis
Val. Contri.(%) to IPM 42% 4% 1%
Medium Cipla, GlaxoSmithKline, Piramal Medley, Apex, Unique Serum Institute, British
10-20% Healthcare, Ipca labs, Aristo Pharma, Janssen Cilag, Jagson Biological, Serdia, Walter
Pharma, Lupin Ltd., Torrent Pal, Wallace, Maneesh Bushnell, Pharmed,
Pharma, AstraZeneca, FDC, Pharma, Fourts India, Natco Pharma,
Ranbaxy, Wockhardt, Emcure, Biochem, Raptakos Brett, Universal, Johnson &
Cadila Pharma Modi Mundi Pharma, Johnson, Anglo French
Bestochem, Ajanta Pharma, Drugs
Charak Pharma, Panacea
Biotech, Albert David
Val. Contri.(%) to IPM 34% 6% 2%
Low Himalaya Drug Shreya Lifescience, CFL, Biological E, Bayer
<10% Dabur, Ind-Swift Pharma Ltd., Dey S,
Paras, RPG Life Sciences
Val. Contri.(%) to IPM 1% 1% 1%

Companies that have moved up the grid, Companies that have moved down the grid,
18
New companies that have entered the grid, Companies that have remained in the same grid
 ACUTE SEGMENT GROWTH DRIVERS

20 (19)
18

16
8
14
(12)
12 (11)
% growth

NI growth%
10
Price led growth %
Volume led growth%
8 8
8
6
11
4

2
3 2
0
Jun'08 MAT Jun'09 MAT Jun'10 MAT

Figures in () indicate value growth of IPM in %

19
 CHRONIC SEGMENT GROWTH DRIVERS
25
(23)
(20)
20
7
7 (14)
15 1
NI growth%
2
% growth

7 Price led growth %

10
Volume led growth%
2 15
5 11
6

0
Jun'08 MAT Jun'09 MAT Jun'10 MAT

Figures in () indicate value growth of IPM in %

20
 Table 7:
Top 10 Therapy segments in the
IPM

21
 Val. Contri. % Val. Gr. %
Rank
(G/L
No. of Val/NI CAGR
over Therapy
NIs (Rs. Cr) * (%)
last JUN’09 JUN’10 JUN’09 JUN’10
year) MAT MAT MAT MAT

IPM 36,631 43,823 11 20 4,562 0.6 15

([Link]) ([Link])
1 Anti Infectives 17.5 17 9 16 705 0.64 14
2 Cardiac 11.3 11.4 14 21 354 0.54 19
3 Gastro Intestinal 10.9 10.9 11 20 555 0.37 14
4 Respiratory 8.9 8.9 11 20 430 0.65 14
5 Pain/Analgesics 8.7 8.6 10 19 568 0.51 12
6 Vitamins/ Minerals/ Nutrients 7.7 7.8 8 21 361 0.95 12
7 Gynaecology 5.8 5.8 14 20 287 0.71 17
8(+2) Anti Diabetic 5.3 5.7 15 29 116 1.51 23
9 Neuro/CNS 5.5 5.6 13 22 230 0.47 17
10(-2) Derma 5.5 5.5 15 19 337 0.5 15

*Note: CAGR is drawn over a period of 4 years

22
 INSIGHTS

Anti Diabetic segment is the fastest growing and most

promising segment and most important growth driver
for IPM.

All chronic therapies (>20%) are contributors while

most acute therapies (<20%) are dilutors to the growth
of IPM.

There is high emphasis on New Introductions which is

a key to growth of IPM with the average value/NI
increasing for most therapies.

23
 Chart 10:
Growth drivers of Top 10
Therapy segments in the IPM

24
 Chart10:Growth drivers of Top 10 Therapy segments in IPM
Figures in () indicate value growth of IPM in %
35
(29)
30
25 (20) (21) (20) (20) (19) 9 (22)
(21) (20)
(16) (19)
20 5 2 5
7 5
15 7 8 12 9 2 8
2 9
1
% Growth

10 2 3 1
17 2 2 18
13 15
5 12 12 10
9 8 7 8
0
-3
es ac a l y s
nt
s y tic NS a
IP
M v di tin to
r sic og e C rm
-5 ec
ti r s a lg e
tri
e ol b o/ e
nf Ca nt
e ir
na ec Di
a
ur D
I I sp Nu a e
ti tro Re n/
A
als/
Gy
n nti N
An a s P a i
er
A
G in
M
n s/
i
a m
V it

NI Growth% Price led Growth% [Link]%

25
 INSIGHTS
Anti Diabetic and Cardiac segments have shown
tremendous volume growth which reflects the
potential of chronic therapy in today’s market.

Anti Infective segment has shown negative price led

growth due to price reduction which is indicative of
high competition in this segment.

IPM is driven by volume and NI growth rather than price led

growth which is indicative of a healthy industry and good
future prospects.

26
Anti-infectives Therapy

27
 Top 5 companies in the Anti-infectives Therapy Market
Figures in ( ) indicate rank as per Jun ‘ 09 MAT
Company Val. Mkt. Val. Brands > Rs. 10 Cr. Top Brand Value of
(Rs. Share Gr. Top
Cr.) (%) (%) Brand
No. Value Contri. (Rs. Cr.)
(Rs. To
Cr.) Portfolio
(%)
Anti-infectives 7,467 100 16 160 4,772 64 AUGMENTIN 158
RANBAXY (1) 760 10.2 13 16 650 85 MOX 126
ALKEM (2) 715 9.6 15 15 571 80 TAXIM 133
ARISTO PHARMA (3) 503 6.7 22 7 422 84 MONOCEF 136
CIPLA (4) 464 6.2 19 10 316 68 NOVAMOX 85
GLAXOSMITHKLINE (5) 416 5.6 23 6 391 94 AUGMENTIN 158

• Augmentin (GSK) being the top brand in the Anti-infectives segment, Ranbaxy still
holds No.1 position.
• Value growth of GSK has been the highest at 23%. 28
 Value (Rs. Cr.)of Top 5 Companies in the
Anti-infectives Therapy Market

416 760
(5.6%) Rank as per Jun ‘ 09 MAT
(10.2 %)
Ranbaxy (1)
464 Alkem (2)
Aristo pharma (3)
(6.2%)
Cipla (4)
GSK (5)
(6.7%)
503 715
(9.6%)

Anti-infectives Val. (Rs. Cr.) = 7,467

Figures in ( ) indicate Market Share (%)
29
Cardiac Therapy

30
 Top 5 Companies in the Cardiac Therapy Market
Figures in ( ) indicate rank as per Jun ’09 MAT

Brands > Rs. 10 Cr

Value of
Val Mrkt Val
Contri to Top
Company (Rs. Share Gr. Value Top Brand
No. Portfolio Brand
Cr) (%) (%) (Rs. Cr)
(%) (Rs. Cr)
CARDIAC 5006 100 21 123 2769 55 STORVAS 97
Sun Pharma (2) 329 6.6 27 11 213 65 AZTOR 39

Torrent Pharma (1) 317 6.3 18 9 191 60 DILZEM 47

Zydus Cadila (3) 301 6.0 22 6 212 70 ATEN 82

Unichem (6) 286 5.7 28 6 181 63 LOSAR-H 63
Cipla (4) 275 5.5 17 6 147 53 AMLOPRES 44

31
 Insights
0 Storvas is the top brand in Cardiac segment but Ranbaxy
does not feature in top 5 companies.
0 Sun Pharma, with a bigger product basket (11 Brands)
leads the market.
0 Storvas and Aztor both are among the top brands thus
indicating good acceptance of dyslipidaemics in the
market.
0 With Dilzem, Aten and Amlopres featuring in top 5
brands, is indicative of good anti anginal therapy market.
0 The top 3 companies have managed to remain in the top
positions since last year.
0 Unichem has shown a high growth rate and has moved up
to number 4.
32
Gastro Intestinal Therapy

33
 Top 5 companies in the Gastro Intestinal Therapy Market

Figures in ( ) indicate rank as per Jun ’09 MAT

Brands>10 Cr
Value
Value Mkt Value of Top
Company (Rs. Share Growth No. Value Contri. to Top Brand Brand
Cr.) (%) (%) (Rs. portfolio (Rs.
Cr.) (%) Cr.)

Gastro Intestinal 4771 100 20 103 2687 56 Zinetac 99

ABBOTT (1) 291 6.1 18 9 265 91 Digene 92
ZYDUS CADILA (2) 265 5.6 24 7 194 73 Ocid 52
DRL (3) 231 4.8 23 6 193 84 Omez 92
ALKEM (5) 213 4.5 38 5 158 74 Pan 59
Zenflox-
MANKIND (6) 198 4.1 29 3 62 31 28
OZ

34
 Insights
0 Zinetac is the top brand in GI segment but GSK does not
feature in top 5
0 Mankind with just 3 brands greater than 10 crores has
made it top 5
0 Ocid, Omez and Pan are among the top brand thus
indicating good acceptance of PPI in the market.
0 Abbott has 91% brands above 10 crores, possibly the
reason why it is placed at the top in GI category
0 The top 3 companies have managed to maintain their
positions since last year
0 Alkem has shown a high growth rate and has moved up
a spot to number 4
35
Respiratory therapy Market

36
 Table 11: Top 5 Companies in Respiratory Therapy
Market
Mkt Val. Value of
Company Value Share Growth Brands > Rs10 cr Top Brand top brand
(Rs cr.)
(%) (%) (Rs. Cr.)
Value Contribution
No. (Rs. Cr) to portfolio(%)
Respiratory 3895 100 20 72 2258 58 Corex 204
Cipla 715 18.4 16 13 553 77 Asthalin 126

Piramal 311 8 15 4 277 89 Phenesedyl 203

Cough
Pfizer 249 6.4 23 2 223 89 Corex 204
Zydus
173 4.4 23 3 102 59 Deriphylline 62
Cadila
GSK 168 4.3 9 6 115 69 Cetzine 41

37
 INSIGHTS

0 Companies having a Value growth of more than 20 % are the

growth drivers of respiratory segment.

0 Pfizer and Zydus Cadila are the growth drivers among top 5
companies.

0 Pfizer and Piramal Healthcare are highly vulnerable because

of their high dependence on one brand in their portfolio (89%)

0 Top 5 companies in Respiratory segment contribute to 40% of

market.

38
Anti-Diabetic Therapy Market

39
 Top 5 companies in the Anti-diabetic Therapy Market
Figures in ( ) indicate rank as per Jun ’09 MAT

Brands > Rs. 10 crore

Market Value of
Value Growth Top
Company (Rs. Cr.) Share (%) No. Contri. To Top brand Brand
(%) Value portfolio
(Rs. Cr.) (Rs. Cr.)
(%)

Anti Diabetic 2500 100 29 63 1614 65 Human Mixtard 30/70 157

Abbott (1) 442 17.7 20 10 393 89 Human Mixtard 30/70 157

USV (2) 272 10.9 30 9 231 85 Glycomet 66

Sanofi Aventis (3) 199 7.9 31 5 184 93 Lantus 68

Sun Pharma (4) 175 7 28 6 138 79 Glucored 45

Eli Lilly (5) 113 4.5 23 3 85 76 Huminsulin 30/70 63

40
Top companies in Each Zone

41
 TOP COMPANIES IN EACH ZONES
RANK IPM NORTH EAST WEST SOUTH
1 CIPLA CIPLA ALKEM CIPLA RANBAXY
2 RANBAXY RANBAXY GSK PIRAMAL (1) CIPLA
3 GSK PIRAMAL PIRAMAL (1) ZYDUS (2) SUN
4 PIRAMAL GSK RANBAXY(-1) GSK (-2) GSK
5 ZYDUS MANKIND SUN PFIZER (2) ZYDUS
6 SUN ZYDUS ZYDUS (1) RANBAXY (-2) ABBOTT (1)
7 ALKEM LUPIN CIPLA (-1) EMCURE (-1) PIRAMAL (-1)
8 PFIZER PFIZER ALEMBIC (2) SUN (1) DRL (1)
9 MANKIND (2) ALKEM (2) ARISTO FDC (-1) MICROLABS (-1)
10 ABBOTT SUN PFIZER (-2) MANKIND (3) PFIZER

42
 INSIGHTS
0 Market leader Cipla is doing well in most markets
except east
0 Similarly Ranbaxy is doing well in most markets
except west, and Piramal in south
0 Companies such as Microlabs and Dr Reddy’s
laboratories have a grip on south market only, and are
not in top ten in other markets.

43
Top 10 co. across town classes

44
 Top 10 companies across Companies

Rank Metro Class I Class II-VI Rural

1 Ranbaxy Cipla Cipla Cipla
Piramal Piramal
2 Cipla Ranbaxy Healthcare Healthcare
3 Sun Pharma GSK GSK GSK
4 Zydus Cadila Piramal Ranbaxy Mankind
Healthcare
5 Pfizer Zydus Cadila Mankind Ranbaxy
6 GSK Sun Pharma Alkem Alkem
7 Piramal Alkem Zydus Cadila Zydus Cadila
Healthcare
8 Sanofi Aventis Lupin Sun Pharma Aristo Pharma
9 Abbott Pfizer Aristo Pharma Pfizer
10 Lupin Abbott Pfizer Abbott

 GSK has a stronger hold in Class I-IV & Rural areas than in Metro
 Pfizer & Abbott trying to penetrate the class I-IV & Rural market
 Growing presence of MNCs can be seen in rural areas
45
Hospital Segment Performance

46
Contribution of SSA and HSA in the IPM
Figures in ( ) are value growth %
Rs. 31,173 Cr. Rs. 35,464 Cr. Rs. 39,786 Cr.
.
% Contribution

100% Rs. 48,136 Cr

7 (16) 7 (12) 8 (21) 9 (37)
90%

80%

70%

60%

50%
93 (14) 93 (14) 92 (11) 91 (20)
40%

30%

20%

10%

0%
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT

HAS SSA
47
 Hospital Segment Performance

0 Hospital segment has registered a robust value growth of 37% (Jun

10 MAT) as compared to last year’s 21% (Jun 09 MAT).

0 Hospital segment contributed 9% to the total IPM (SSA + HAS) as

per Jun’10 MAT.

0 The trend for past 4 years showed an upward trend in this

contribution from Jun’07 MAT to Jun’10 MAT, which supports the
fact that Hospital sector is gaining importance in the IPM and as a
result more players are strengthening their focus towards this
sector.

0 In terms of growth, Hospital sales showed high growth of 37%

growth as per Jun’10 MAT
48
 Top Companies in Hospital Market

HSA rank Jun ‘10 MAT Company Value Val Gr.

(HSA rank Jun ‘07 MAT)
( Rs. Cr.) ( %)
IPM 4,313 37
1 (1) GlaxoSmithKline 251 35
2 (6) Sun Pharma 240 60
3 (2) Cipla 228 44
4 (5) Zydus Cadila 189 39
5 (3) Pfizer 189 57
6 (9) Piramal Healthcare 180 44
7 (4) Sanofi Aventis 178 48
8 (8) Ranbaxy 165 46
9 (10) Lupin Limited 156 39
10 (7) Alkem 137 16
49
 Insights
0 There is a considerable shift in the ranks of companies
in the hospital segment
0 Sun pharma, Sanofi Aventis and Alkem has the
greatest had the greatest change in the ranking.

50
 Top therapies in hospital market
Rank Value contribution(%) Value growth (%)
(G/L) over Therapy June ‘09 June ‘10 June ‘09 June ‘10 CAGR (%)
last year) MAT MAT MAT MAT
IPM 3155 Crs 4313 Crs 21 37 23
1 Anti infectives 26.8% 25.6% 18 30 20
2 Cardiac 11.11% 11.8% 19 45 25
3 Gastro 8.3% 8.1% 21 34 19
intestinal
4 Pain/Analgesic 7.4% 7.2% 21 33 22
s
5 Gynaec 6.0% 5.9% 26 34 21
6 Respiratory 5.9% 5.6% 38 30 29
7(+1) Neuro/CNS 5.0% 5.4% 29 49 31
8 (-1) Vitamins/Mine 5.1% 5.0% 18 32 18
rals/Nutrients
9 Others 4.3% 4.9% 11 57 31
10 Anti diabetic 3.5% 4.1% 21 58 35

51
 Insights
0 All the top 10 therapies have recorded a robust
double digit growth i.e. more than 30% growth.
0 Neuro and CNS increased the contribution by 0.4%
0 New introductions added an incremental value of Rs.
300 Cr. which constitutes 26% of the total incremental
value.

52
 Specialty – wise prescription split

Specialty Rx contribution%
Jun ‘ 09 MAT Jun ‘10 MAT
All Specialties 156 crs 164 crs
General 40.2% 40.1%
practitioners
Mass specialties 28.6 % 28.6%
Super specialties 31.1% 31.3%

53
 70
65.76

60 62.71
Highest Rx
51.33 contribution was
50 46.9
48.52 obtained from
44.62 general
40
practitioners .
In Jun’10 general
Rx contribution 30
Jun '09 MAT practitioners
Jun'10 MAT
added more
20
number of
prescriptions
10 (3.1cr).

0
General Mass Super
practitioners specialities specialities

All specialties

54
 Top therapies in IPM
Therapies Rx contribution %
Total Rx [Link] Super Mass
(Rs. Cr.) specialties specialties
Total 164 40% 31% 29%
Anti infective 63 50% 24% 26%
Cardiac 9 20% 42% 38%
Gastro intestinal 51 43% 26% 31%
Respiratory 37 49% 18% 33%
Pain/analgesics 61 40% 36% 25%
Vitamins / Minerals / Nutrients 30 38% 28% 35%
Gynecology 11 30% 12% 58%
Anti Diabetic 4 14% 42% 44%
Neuro / CNS 11 21% 53% 27%
Derma 9 34% 36% 30%

55
 Anti Diabetic 4

Cardiac 9

Derma 9

Neuro / CNS 11 Currently , anti

Gynaecology 11
infective therapy
is the growth
Therapies Vitamins/ Minerals / Nutrients 31 driver of IPM
Total Rx in cr.

Respiratory 37

Gastro intestinal 51

Pain / analgesics 61

Anti infective 63

0 10 20 30 40 50 60 70

Total Rx in cr.

56
 Anti Diabetic
GPs - highest
Cardiac prescription
contribution: Anti
Neuro / CNS infective therapy
Gynaecology
Super specialties -
Derma
highest
prescription
Mass specialties
Vitamins / Minerals / Nutrients contribution:
Super specialties
G.P.
neuro/CNS
Pain / Analgesics
therapy
Gastro intestinal
Mass specialties -
Respiratory highest
prescription
Anti infective contribution:
0% 10%20%30%40%50%60%70%
Gynaecology
Rx contribution %

57
Top co. in IMS Rx Audit
Figures in ( ) are value growth %
Rx contribution (%)
Rank Companies Total IPM =
Jun '09 MAT Jun '10 MAT 43823 Cr.
  IPM 156 Cr. 164 Cr. Total Rx IPM =
164 Cr.
1 (1) GSK 10.8% 10.7%
2 (2) Cipla 10.1% 9.9%
3 (4) Mankind 8.1% 9.2% Rx IPM
contributes to
4 (3) Piramal Healthcare 8.9% 8.8%
0.3% of total
5 (5) Zydus Cadila 7.1% 7.1% IPM
6 (6) Ranbaxy 7.0% 6.7%
7 (7) DRL 6.6% 6.6%
Indicating a
8 (8) FDC 6.1% 5.9% heavy trend of
9 (9) Alkem 5.3% 5.6% OTX selling in
India
10 (11) Sun Pharma 4.7% 4.9%

58
 Top co. in Prescription Audit

Insights
0 Rx IPM contributes to 0.3% of total IPM (Jun ‘10 MAT)
0 The total contribution of Rx to IPM is low. Indicating a
heavy trend of OTX.
0 GSK & Cipla have managed to be doctor’s favorite
while prescribing.
0 Mankind has grown by leaps and bound each year
even in Rx market. Indicating good acceptance among
doctors.
0 GSK is the only MNC that features among the top 10
(Assumption: Piramal & Ranbaxy started as Indian
and later acquired by MNC)
59
 Prescription & Prescriber Dispersion
June '10 MAT
Rx contri (%) Rxber contribution (%)
Total 164 Cr. 244000
GP Total 66 Cr. 94000
GP (Non MBBS) 65% 69%
GP (MBBS) 35% 32%
MASS SPECIALITIES 47 Cr. 65000
Gynaecologist 27% 34%
CP 30% 28%
Paediatrician 28% 23%
Gen. Surgeon 14% 16%
SUPER SPECIALITIES 51 Cr. 85000
Dentist 29% 33%
Orthopaedic 12% 12%
Opthamologist 9% 11%
ENT Specialist 8% 8%
Cardiologist 6% 7%
Dermatologist 6% 6%
Chest TB Specialist 4% 5%
Neurologist Neuro Surgeon 3% 5%
Nephrologist Urologist 3% 4%
Diabetologist Endocrinologist 3% 3%
Psychiatrist 3% 3%
Gastroenterologist 3% 3%
Oncologist 1% 2%
60
 Prescription & Prescriber Dispersion

Insights

0 Max. prescribers are GP (Non MBBS) – Might indicate

patients price sensivity towards Doctor’s fees.
0 Top 3 Rxber contribution
(1) GP (Non-MBBS) (2) Gynaecs (3) Dentists
0 Barring dentists the overall superspeciality size is
comparitively smaller.

61
Indian Vaccine Market - An Overview

62
 Indian Pharmaceutical Market 19.6% Gr ,highest
since 4 years,
- An Overview CAGR- 15.2%

Total IPM & Incremental Value (in Rs. Cr.) YoY

Val. (Rs. Cr.)

63
Source: IMS – June’10 MAT
 Growth
Vaccine Market - Trend double
than last
year
Val. (Rs. Cr.) (53)

(24)
(>>) (-2)

June MAT
Source: IMS – June’10 MAT 64
Fig ( ):% Val Gr
 Vaccine Market: Dispensing doctors &
Hospitals drive market

Business Channels

(53 (-
)(48 27)
(96
) )
(41
) (>>)

(10
) (19
)

Source: IMS – June’10 MAT 65

Fig ( ):% Val Gr
 MNCs
drive
Vaccine Market:Indian Vs MNCs market

(21) (38)

(27) (64)

Source: IMS – June’10 MAT 66

Fig ( ):% Val Gr
 Top 10
Vaccine Market: Top 10 Companies contributes
90%

Rank Company Val. Market Val.

June’10 (Rs. Cr.) Share % Growth %
MAT
Vaccine Market 726 100% 53
1 GSK 131 18% 23
2 Sanofi Aventis 129 18% >>
3 Pfizer 71 10% 75
4 Novartis 68 9% -12
5 Serum Institute 68 9% 40
6 Panacea Biotech 59 8% 57
7 VHB Lifesciences 33 5% >>
8 Zydus Cadila 32 4% 56
9 MSD 31 4% >>
10 Shantha Biotech 24 3% 15

67
 Vaccine Market :Top Therapies
Therapies Value Share % Val. Grwth % Incr. Val. (Rs. Cr.)
(Rs. Cr.) June’09 June’10 June’09 June’10
MAT MAT MAT MAT
Vaccine 726.1 100% 24 53 93 250
Market
Toddler 211 29% 55 60 47 79
Vaccine
Adult 205 28% -4 22 -7 37
Vaccine
Paediatric 146 20% 67 >> 28 77
Combinati
on
Vaccines
Paediatric 131 18% 25 32 20 32
Single
Vaccines
All Other 33 5% --- 431 6 27
Vaccines

68
 Top 10

Vaccine Market: Top 10 Brands contributes

--50%
Rank Brands Company Val. Val. Growth % Incr. val. (Rs. Cr.)
June’1 (Rs. Cr.)
0 MAT
June’09 June’10 June’09 June’10
Mat MAT Mat MAT

Vaccine 726 24 53 93.1 250

Market
1 Prevenar Pfizer 71 150 75 24 30
2 Rabipur Novartis 68 4 -12 3 -9
3 Pentaxim Sanofi 46 >> >> 7 39
Aventis
4 Havrix GSK 37 9 47 2 12
5 Varivax VHB 33 59 >> 5 18

6 Vaxirab Zydus Cadila 32 -11 56 -3 11

7 Varil Rix GSK 25 -3 -9 -1 -2

8) Gardasil MSD 22 ---- >> 5 16
9 Verorab Sanofi 21 ---- ---- 0 21
Aventis
10 Rotarix GSK 21 ---- >> 10 69
11
 NIs 7.55%

Vaccine Market : Top 10 NIS contr,

NIs Comapny Launch Value Incr.

Date (Rs. Cr.) Val.
YYYY MM (Rs. Cr.)
Vaccine Market 104 79
Gardasil MSD 2008 10 22 16
Rotarix GSK 2008 07 21 11
Pentavac Serum Institute 2008 10 16 12
Cervarix GSK 2009 02 11 10
Polprotec Panacea Biotech 2008 07 9 6
Xprab RANBAXY 2009 10 7 7
Quadrovax Serum Institute 2008 11 4 3
Comvac- 5 Bharat Biotech 2009 02 3 3
Pentavac - SD Serum Institute 2009 11 2 2
Shan HIB- DPT Shantha Biotech 2008 09 2 1

70